Uppsala 7th May 2019
Nanexa publishes an article on PharmaShell® in an international scientific journal
Nanexa together with AstraZeneca has published a scientific article in the scientific journal European Journal of Pharmaceutics and Biopharmaceutics. The article presents results from various studies that show the possibilities of creating long depot preparations with controlled drug release using PharmaShell®. The article is titled “Nanoshells Prepared by Atomic Layer Deposition – Long Acting Depots of Indomethacin”, and summaries can be found at https://doi.org/10.1016/j.ejpb.2019.04.019
Nanexa’s CEO David Westberg comments:
I have previously communicated that our collaboration with AstraZeneca is in an exciting phase and this publication is part of that collaboration. It is important for us to communicate information about PharmaShell® in different ways and we know that information from scientific articles is confidence building. By publication in a journal relevant to the industry, we also reach out to people in senior positions at the pharmaceutical companies’ development departments, which can provide great benefits.
The article has gone through the usual peer review procedure that applies to scientific articles and the fact that we passed it through the needle eye provides in my eyes further evidence of the unique potential of PharmaShell® technology.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: firstname.lastname@example.org
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.